These findings suggest that targeting SHMT2 to modulate glycine levels may be a potential therapeutic strategy for MASLD and other hepatic disorders (Ghrayeb et al., 2024, McBride et al., 2024). Here, SHMT2 is linked to metabolic dysfunction-associated steatotic liver disease.